The combined administration of DMBA + MPA has a tumor formation rate of 50%, Immunohistochemistry: ER (+), PR (+), CK5/6 (+), Her-2 (–). PTEN and PIK3C genes are frequently mutated in this breast cancer model. The gene discussed is KRT5; the disease is breast carcinoma.